Association of Structural Forms of 17q21.31 with the Risk of Progressive Supranuclear Palsy and Sub-haplotypes.

Journal: medRxiv : the preprint server for health sciences

Volume: 

Issue: 

Year of Publication: 

Affiliated Institutions:  Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Bioinformatics Research Center, North Carolina State University, NC, USA. Department of Pathology, Department of Artificial Intelligence & Human Health, Nash Family, Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain, Institute, Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Victorian Brain Bank, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia. Alzheimer's disease and other cognitive disorders unit. Neurology Service, Hospital Clínic, Fundació Recerca Clínic Barcelona (FRCB). Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. Movement Disorders Program, Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, University of Antwerp, Wilrijk (Antwerp), Belgium. Fujirebio Europe NV, Technologiepark , Gent, Belgium. Department of Pathology and Laboratory Medicine and Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. Netherlands Brain Bank and Erasmus University, Netherlands. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. London Neurodegenerative Diseases Brain Bank, King's College London, London, UK. Autonomous University of Madrid, Madrid, Spain. Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas) - Centro Alzheimer Fundación Reina Sofía, Madrid, Spain. Department of Neurology, Philipps-Universität, Marburg, Germany. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. Parkinson's disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece. Department of Psychiatry and Psychotherapy, University Hospital Munich, Ludwig-Maximilians-University Munich, Germany. German Brain Bank, Neurobiobank Munich, Germany. Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U, CNRS UMR , APHP - Hôpital Pitié-Salpêtrière, Paris, France. Banner Sun Health Research Institute, Sun City, AZ, USA. University McGill, Montreal, Quebec, Canada. Department of Neuroscience, University of California, San Diego, CA, USA. VIB Center for Molecular Neurology, University of Antwerp, Belgium. Department of Neuroscience, Mayo Clinic Jacksonville, FL, USA. Memory and Aging Center, University of California, San Francisco, CA, USA. University of Texas Southwestern Medical Center, Dallas, TX, USA. Departmento of Clinical and Movement Neuroscience, University College of London, London, UK. Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK. Department of Genetics and Genomic Sciences, New York, NY, USA; Icahn School of Medicine at Mount Sinai, New York, NY, USA. Friedman Bioventure, Inc., Del Mar, CA, USA: Department of Genetics and Genomic Sciences, New York, NY, USA.

Abstract summary 

The chromosome 17q21.31 region, containing a 900 Kb inversion that defines H1 and H2 haplotypes, represents the strongest genetic risk locus in progressive supranuclear palsy (PSP). In addition to H1 and H2, various structural forms of 17q21.31, characterized by the copy number of α, β, and γ duplications, have been identified. However, the specific effect of each structural form on the risk of PSP has never been evaluated in a large cohort study.To assess the association of different structural forms of 17q.21.31, defined by the copy numbers of α, β, and γ duplications, with the risk of PSP and sub-haplotypes.Utilizing whole genome sequencing data of 1,684 (1,386 autopsy confirmed) individuals with PSP and 2,392 control subjects, a case-control study was conducted to investigate the association of copy numbers of α, β, and γ duplications and structural forms of 17q21.31 with the risk of PSP. All study subjects were selected from the Alzheimer's Disease Sequencing Project (ADSP) Umbrella NG00067.v7. Data were analyzed between March 2022 and November 2023.The main outcomes were the risk (odds ratios [ORs]) for PSP with 95% CIs. Risks for PSP were evaluated by logistic regression models.The copy numbers of α and β were associated with the risk of PSP only due to their correlation with H1 and H2, while the copy number of γ was independently associated with the increased risk of PSP. Each additional duplication of γ was associated with 1.10 (95% CI, 1.04-1.17; = 0.0018) fold of increased risk of PSP when conditioning H1 and H2. For the H1 haplotype, addition γ duplications displayed a higher odds ratio for PSP: the odds ratio increases from 1.21 (95%CI 1.10-1.33, = 5.47 × 10) for H1β1γ1 to 1.29 (95%CI 1.16-1.43, = 1.35 × 10) for H1β1γ2, 1.45 (95%CI 1.27-1.65, = 3.94 × 10) for H1β1γ3, and 1.57 (95%CI 1.10-2.26, = 1.35 × 10) for H1β1γ4. Moreover, H1β1γ3 is in linkage disequilibrium with H1c (R = 0.31), a widely recognized sub-haplotype associated with increased risk of PSP. The proportion of sub-haplotypes associated with increased risk of PSP (i.e., H1c, H1d, H1g, H1o, and H1h) increased from 34% in H1β1γ1 to 77% in H1β1γ4.This study revealed that the copy number of γ was associated with the risk of PSP independently from H1 and H2. The H1 haplotype with more γ duplications showed a higher odds ratio for PSP and were associated with sub-haplotypes with increased risk of PSP. These findings expand our understanding of how the complex structure at 17q21.31 affect the risk of PSP.

Authors & Co-authors:  Wang Chang Dombroski Cheng Si Tucci Patil Valiente-Banuet Farrell Mclean Molina-Porcel Alex Paul De Deyn Le Bastard Gearing Donker Kaat Van Swieten Dopper Ghetti Newell Troakes G de Yébenes Rábano-Gutierrez Meller Oertel Respondek Stamelou Arzberger Roeber Müller Hopfner Pastor Brice Durr Ber Beach Serrano Hazrati Litvan Rademakers Ross Galasko Boxer Miller Seeley Van Deerlin Lee White Morris de Silva Crary Goate Friedman Leung Coppola Naj Wang Dickson Höglinger Tzeng Geschwind Schellenberg Lee

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. Clin Exp Optom. 2011;94(2):150–160. doi:10.1111/j.1444-0938.2010.00504.x
Authors :  64
Identifiers
Doi : 2024.02.26.24303379
SSN : 
Study Population
Male,Female
Mesh Terms
Other Terms
17q21.31;Copy number variation (CNV);H1 and H2 haplotypes;MAPT;Progressive Supranuclear Palsy (PSP)
Study Design
Cohort Study
Study Approach
Country of Study
Publication Country
United States